Truvada Lawsuit Settlement Amounts — April 2026 Update

Truvada Settlement Status — April 2026

No global settlement has been reached in the Truvada/TDF litigation as of April 2026. Cases are actively being litigated in California state court (JCCP 5043) and various federal jurisdictions.

The litigation continues to grow as more HIV patients discover the connection between TDF medications and their kidney or bone problems.

Estimated Settlement Ranges

Based on the severity of injuries and comparable pharmaceutical litigation:

Case Severity	Estimated Range	Typical Profile
Tier 1 (Catastrophic)	$250,000 — $1,000,000+	Kidney failure requiring dialysis or transplant, severe bone fractures, wrongful death
Tier 2 (Severe)	$150,000 — $400,000	Significant chronic kidney disease, multiple fractures, ongoing impairment
Tier 3 (Significant)	$75,000 — $200,000	Documented kidney damage, bone density loss, manageable conditions
Tier 4 (Moderate)	$30,000 — $100,000	Documented adverse effects, subclinical damage, monitoring required

These projections are based on similar pharmaceutical litigation. Individual amounts depend on case specifics.

Comparable Pharmaceutical Settlements

Lawsuit	Injury	Per Plaintiff
Vioxx	Heart attack	~$120,000
Risperdal	Gynecomastia	$1.5M — $8B (varied)
Actos	Bladder cancer	~$240,000
Belviq	Cancer	$50k — $300k

Factors That Affect Individual Settlement Value

• Severity of kidney damage — From mild dysfunction to kidney failure
• Severity of bone damage — From osteopenia to severe fractures
• Duration of TDF use — Longer use strengthens causation
• Need for dialysis or transplant — Major value drivers
• Permanent impairment — Lasting disability
• Medical expenses — Past and projected costs
• Age at injury — Younger plaintiffs may have higher lifetime damages
• Use pattern — Treatment vs. PrEP, single drug vs. combination

Why Truvada Cases May Have Strong Value

Several factors support potentially substantial settlements:

1. Strong scientific evidence — TAF safety vs. TDF is well-documented
2. Internal documents — Discovery has revealed Gilead's awareness of TAF safety
3. Compelling allegations — Delaying a safer drug to maximize profits
4. Severe injuries — Kidney failure has lifelong consequences
5. Sympathetic plaintiffs — HIV patients trusted to receive the best treatment
6. Massive defendant — Gilead has substantial financial resources

The Core Allegation

The most powerful aspect of the Truvada litigation is the allegation that Gilead deliberately delayed releasing TAF:

• TAF was reportedly developed in the early 2000s
• Internal documents allegedly show Gilead knew TAF was safer
• TAF wasn't released until 2015
• This delay allegedly extended TDF profits at patient expense
• Thousands of patients suffered avoidable kidney and bone damage

This allegation of corporate misconduct could lead to higher settlements and potential punitive damages.

Expected Timeline

1. Current phase: Active litigation in California and federal courts
2. Bellwether trials: Some have occurred, more expected
3. Settlement negotiations: May intensify after additional trial results
4. Individual resolution: 2-4 years for most claimants

What You Should Do Now

• Gather pharmacy records — Document TDF prescriptions and dates
• Get medical testing — Kidney function (creatinine, GFR) and bone density (DEXA scan)
• Document complications — All kidney or bone problems
• Preserve medical records — From all relevant providers
• Get a free case evaluation — Attorneys actively reviewing TDF cases
• File promptly — Statutes of limitations are running

Important: Don't Stop Your HIV Medication

Filing a lawsuit does not require you to stop your HIV treatment. Continue taking your current medications as prescribed. Many patients have safely switched from TDF-based drugs to TAF-based alternatives — discuss this with your HIV specialist.